Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page R1
Diana E. Pankevich, Theresa M. Wizemann, and Bruce M. Altevogt, Rapporteurs Forum on Neuroscience and Nervous System Disorders Board on Health Sciences Policy
OCR for page R2
THE NATIONAL ACADEMIES PRESS • 500 Fifth Street, NW • Washington, DC 20001 NOTICE: The workshop that is the subject of this summary was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. This project was supported by contracts between the National Academy of Sciences and the Alzheimer’s Association; CeNeRx Biopharma; the Department of Health and Human Services’ National Institutes of Health (NIH, Contract No. N01-OD-4-2139) through the National Eye Institute, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and NIH Blueprint for Neuroscience Research; Department of Veterans Affairs; Eli Lilly and Company; Fast Forward, LLC; Foundation for the National Institutes of Health; GE Healthcare, Inc.; GlaxoSmithKline, Inc.; Johnson & Johnson Pharmaceutical Research and Development, LLC; Lundbeck Research USA; Merck Research Laboratories; The Michael J. Fox Foundation for Parkinson’s Research; the National Science Foundation (Contract No. OIA-0753701); One Mind for Research; Pfizer Inc.; the Society for Neuroscience; and Wellcome Trust. The views presented in this publication are those of the editors and attributing authors and do not necessarily reflect the view of the organizations or agencies that provided support for this project. International Standard Book Number-13: 978-0-309-26633-8 International Standard Book Number-10: 0-309-26633-5 Additional copies of this report are available from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu. For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu. Copyright 2013 by the National Academy of Sciences. All rights reserved. Printed in the United States of America The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The serpent adopted as a logotype by the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche Museen in Berlin. Suggested citation: IOM (Institute of Medicine). 2013. Improving the utility and translation of animal models for nervous system disorders: Workshop summary. Washington, DC: The National Academies Press.
OCR for page R3
OCR for page R4
The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences. The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. Charles M. Vest is president of the National Academy of Engineering. The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine. The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. Charles M. Vest are chair and vice chair, respectively, of the National Research Council. www.national-academies.org
OCR for page R5
PLANNING COMMITTEE ON IMPROVING TRANSLATION OF ANIMAL MODELS FOR NERVOUS SYSTEM DISRODERS1 RICHARD J. HODES (Co-Chair), National Institute on Aging STEVEN M. PAUL (Co-Chair), Weill Cornell Medical College TIMOTHY COETZEE, National Multiple Sclerosis Society MARK A. GEYER, University of California, San Diego WALTER J. KOROSHETZ, National Institute for Neurological Disorders and Stroke ALAN I. LESHNER, American Association for the Advancement of Science GERARD J. MAREK, Abbott Laboratories WILLIAM Z. POTTER, Foundation for the National Institutes of Health SHARON ROSENZWEIG-LIPSON, IVS Pharma Consulting TODD SHERER, The Michael J. Fox Foundation for Parkinson’s Research DAVID SHURTLEFF, National Institute of Drug Abuse JUDY SIUCIAK, Foundation for the National Institutes of Health STEVIN ZORN, Lundbeck USA IOM Staff BRUCE M. ALTEVOGT, Project Director DIANA E. PANKEVICH, Program Officer ELIZABETH K. THOMAS, Senior Program Assistant (until November 2012) ___________________________ 1 Institute of Medicine planning committees are solely responsible for organizing the workshop, identifying topics, and choosing speakers. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution. v
OCR for page R6
OCR for page R7
FORUM ON NEUROSCIENCE AND NERVOUS SYSTEM DISORDERS1 STEVEN HYMAN (Chair), The Broad Institute SUSAN AMARA, Society for Neuroscience MARC BARLOW, GE Healthcare, Inc. MARK BEAR, Massachusetts Institute of Technology KATJA BROSE, Neuron DANIEL BURCH, PPDi C. THOMAS CASKEY, Baylor College of Medicine TIMOTHY COETZEE, Fast Forward, LLC EMMELINE EDWARDS, NIH Neuroscience Blueprint MARTHA FARAH, University of Pennsylvania RICHARD FRANK, GE Healthcare, Inc. DANIEL GESCHWIND, University of California, Los Angeles HANK GREELY, Stanford University MYRON GUTMANN, National Science Foundation RICHARD HODES, National Institute on Aging STUART HOFFMAN, U.S. Department of Veterans Affairs THOMAS INSEL, National Institute of Mental Health PHILLIP IREDALE, Pfizer Global Research and Development DANIEL JAVITT, Nathan S. Kline Institute for Psychiatric Research FRANCES JENSEN, University of Pennsylvania School of Medicine STORY LANDIS, National Institute of Neurological Disorders and Stroke ALAN LESHNER, American Association for the Advancement of Science HUSSEINI MANJI, Johnson & Johnson Pharmaceutical Research and Development, Inc. DAVID MICHELSON, Merck Research Laboratories RICHARD MOHS, Lilly Research Laboratories JONATHAN MORENO, University of Pennsylvania ATUL PANDE, GlaxoSmithKline, Inc. STEVEN PAUL, Weill Cornell Medical College TODD SHERER, The Michael J. Fox Foundation for Parkinson’s Research PAUL SIEVING, National Eye Institute 1 Institute of Medicine forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution. vii
OCR for page R8
JUDITH SIUCIAK, Foundation for the National Institutes of Health MARC TESSIER-LAVIGNE, The Rockefeller University WILLIAM THIES, Alzheimer’s Association NORA VOLKOW, National Institute on Drug Abuse KENNETH WARREN, National Institute on Alcohol Abuse and Alcoholism JOHN WILLIAMS, Wellcome Trust STEVIN ZORN, Lundbeck USA CHARLES ZORUMSKI, Washington University School of Medicine IOM Staff BRUCE M. ALTEVOGT, Forum Director DIANA E. PANKEVICH, Program Officer ANDREW POPE, Director, Board on Health Sciences Policy viii
OCR for page R9
Reviewers This workshop summary has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the National Research Council’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published workshop summary as sound as possible and to ensure that the workshop summary meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the process. We wish to thank the following individuals for their review of this workshop summary: Nathalie Breysee, Lundbeck Research, USA Malcolm MacLeod, University of Edinburgh David Shurtleff, National Institute on Drug Abuse Rae Silver, Columbia University Mark Tricklebank, Eli Lilly and Company Bart van der Worp, University Medical Center Utrecht Although the reviewers listed above have provided many construc- tive comments and suggestions, they did not see the final draft of the workshop summary before its release. The review of this workshop summary was overseen by Floyd E. Bloom, The Scripps Research Insti- tute. Appointed by the Institute of Medicine, he was responsible for mak- ing certain that an independent examination of this workshop summary was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final ix
OCR for page R10
content of this workshop summary rests entirely with the authors and the institution. x
OCR for page R11
Contents 1 INTRODUCTION AND OVERVIEW 1 2 EVALUATION OF CURRENT ANIMAL MODELS 9 3 TRANSLATION FROM ANIMAL MODELS TO THE CLINIC: CASE EXAMPLES FROM NEUROSCIENCE RESEARCH 21 4 PERSPECTIVES ON STANDARDIZATION 33 5 PERSPECTIVES ON CORRESPONDING ANIMAL AND CLINICAL ENDPOINTS 45 6 ADDRESSING THE TRANSLATIONAL DISCONNECT 55 7 SUMMARY OF WORKSHOP TOPICS 67 APPENDIXES A References 77 B Workshop Agenda 83 C Registered Attendees 93 xi
OCR for page R12